Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$64.90 USD

64.90
175,113

+1.44 (2.27%)

Updated May 31, 2024 04:00 PM ET

After-Market: $64.95 +0.05 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study

by Zacks Equity Research

PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

by Zacks Equity Research

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%

by Zacks Equity Research

Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.

Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data

by Zacks Equity Research

A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.

FTC Challenges Amgen's (AMGN) $28B Acquisition of Horizon

by Zacks Equity Research

Per the FTC, Amgen's (AMGN) acquisition of Horizon (HZNP) would entrench the monopoly positions for the latter's medications for thyroid eye disease and chronic refractory gout.

HCA Healthcare (HCA) Gains 29% in a Year: More Upside Left?

by Zacks Equity Research

HCA Healthcare (HCA) is well-poised for growth on the back of higher revenues, a diversified treatment network and sound operating cash flows.

Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel

by Zacks Equity Research

The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.

ANI Pharmaceuticals (ANIP) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 244.12% and 28.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for March 13th

by Zacks Equity Research

ANIP, ARCB and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2023.

ANI Pharmaceuticals (ANIP) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 11.76% and 8.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

ANI (ANIP) delivered earnings and revenue surprises of 8.33% and 4.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 4% and 21.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy ANI Pharmaceuticals (ANIP) Ahead of Earnings?

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Regenxbio (RGNX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -9.72% and 25.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.

ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ANI (ANIP) Soars 6.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

ANI (ANIP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.